Il-15 fusion protein and mRNA sequence thereof and use thereof

By designing the optimized interleukin 15 fusion protein RLI-mono-hFc and its mRNA sequence, combined with lipid nanoparticle delivery technology, the problem of insufficient biological activity of existing IL15 superagonists was solved, and significant tumor suppression effect was achieved. It has strong anti-tumor potential.

WO2024230591A1PCT designated stage expired Publication Date: 2024-11-14BEIJING NEOCURNA BIOTECHNOLOGY CORP +2
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090839
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-06
Filing Date
2024-04-30
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing IL15 superagonists have shortcomings in terms of biological activity, which is difficult to effectively inhibit tumor growth, and the construction of IL15 superagonists with strong biological activity still needs to be designed and screened.

Method used

Design an interleukin 15 fusion protein, containing IGHE signal peptide, IL-15 receptor Rαsushi domain, CH2 and CH3 segments connecting peptides and Fc monomers, and optimize protein composition to form RLI-mono-hFc, and bind mRNA sequence to use it for Anti-tumor drugs are prepared and lipid nanoparticles are used as delivery vehicles.

Benefits of technology

RLI-mono-hFc significantly improves biological activity, can effectively inhibit tumor growth, is significantly better than recombinant human IL15, has strong anti-tumor potential, and its therapeutic effect is verified through mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024090839-FTAPPB-I100001
    Figure PCTCN2024090839-FTAPPB-I100001
  • Figure PCTCN2024090839-FTAPPB-I100002
    Figure PCTCN2024090839-FTAPPB-I100002
  • Figure PCTCN2024090839-FTAPPB-I100003
    Figure PCTCN2024090839-FTAPPB-I100003
Patent Text Reader

Abstract

Provided is an interleukin 15 fusion protein, which sequentially comprises, from N-terminal to C-terminal, an IGHE signal peptide, an IL-15 receptor Rαsushi domain, a linker peptide 1, an IL-15 functional fragment, a linker peptide 2, CH2 and CH3 fragments of an Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N into D. Also provided are an mRNA of the interleukin 15 fusion protein and the use thereof. By means of optimizing the protein composition of interleukin 15 fusion protein as an IL15 superagonist, higher biological activity is achieved, so that the RLI-mono-hFc can be effectively used for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

IL-15 fusion protein and its mRNA sequence and application

[0001] This application claims the benefit of Chinese patent application No. 2023105074138, filed May 6, 2023. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field

[0002] The present invention belongs to the field of biomedicine technology and relates to mRNA drug sequence design, in particular to an IL-15 fusion protein, an mRNA sequence and applications thereof. Background Art

[0003] Cytokines are a class of secreted proteins that function in regulating cell differentiation and cell activity. Cytokines are particularly important in regulating the human immune system. Cytokines regulate immune system function by influencing the phenotypic differentiation and function of different cells in the immune system. The function of cytokines in the immune system has long been recognized, and attempts have been made to apply them to tumor treatment. Interleukin-15 (IL15) is one of the cytokines with potential anti-tumor effects. IL15 can promote the generation and expansion of NK cells and CD8+ T cells in the body, and activate their immune function. At the same time, IL15 does not enhance Treg cells that suppress immune function. However, IL15 itself has problems such as a short half-life, and IL15 needs to be artificially modified to become an IL15 superagonist to achieve its optimal effect.

[0004] At present, many means can be used to modify IL15 to make it an IL15 superagonist. At present, there are not many reports on this type of drug. For example, the Class 1 new drug FL115 injection reported in 2024 was approved for clinical use by the China National Medical Products Administration (NMPA) and is intended to be developed for the treatment of unresectable locally advanced or metastatic solid tumors. Public information shows that the FL115 injection is an interleukin 15 (IL-15) super immune agonist. IL15 superagonists mainly exist in the form of homologous or heterologous dimers, but on the existing basis, how to construct an IL15 superagonist with strong biological activity is still a task that requires design and screening.

[0005] Summary of the Invention

[0006] Based on this, the purpose of the present invention is to provide an interleukin-15 fusion protein as an IL15 superagonist, which has very strong biological activity and can be used to treat tumors.

[0007] The technical solutions for achieving the above-mentioned purpose include the following.

[0008] An interleukin-15 fusion protein comprises, from N-terminus to C-terminus, the CH2 and CH3 segments of an interleukin-15 (IL-15) receptor Rαsushi domain, a connecting peptide 1, an IL-15 functional fragment, a connecting peptide 2, and an Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N to D, one end of the IL-15 receptor αsushi domain is connected to the IL-15 functional fragment, and the other end of the IL-15 functional fragment is connected to the Fc monomer.

[0009] In some embodiments, the sequence of the IGHE signal peptide is as shown in MDWTWILFLVAAATRVHS (SEQ ID NO: 11).

[0010] In some embodiments, the IL-15 receptor Rα sushi domain is represented by ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPP (SEQ ID NO: 12).

[0011] In some embodiments, the CH2 and CH3 segments of the Fc monomer are as shown in APEFLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTFPPSQEEMTKNQVSLRCLVKGFYPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTFPPSQEEMTKNQVSLRCLVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFRLESRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 13).

[0012] The connecting peptide may be a conventional linker sequence used to connect polypeptides, which can connect two polypeptides and naturally fold them into the desired structure. It is generally a short peptide with a hydrophobic and certain stretchability. The connecting peptide can be flexible. In some embodiments, a flexible connecting peptide is advantageous, as it can connect two amino acid fragments while maintaining their respective activities and functions. In some embodiments, the connecting peptide 1 is shown as ggggsggggsggggsggggs, such as GGGGGGGG, GSLPETGGSRGDGGSL.

[0013] In some embodiments, the connecting peptide 2 is represented by ggggsggggsggggs (SEQ ID NO: 14).

[0014] In some preferred embodiments, the amino acid sequence of the interleukin-15 fusion protein is shown as SEQ ID NO.1.

[0015] The second aspect of the present invention provides the mRNA of the interleukin-15 fusion protein.

[0016] In some embodiments, the mRNA of the interleukin-15 fusion protein is shown as SEQ ID NO.9.

[0017] In some embodiments, the IGHE signal peptide is linked to the IL-15 receptor Rαsushi domain via gs.

[0018] The third aspect of the present invention provides the use of the interleukin-15 fusion protein in the preparation of anti-tumor drugs.

[0019] The fourth aspect of the present invention provides the use of the interleukin-15 fusion protein mRNA in the preparation of anti-tumor drugs.

[0020] The fifth aspect of the present invention provides an anti-tumor drug.

[0021] An anti-tumor drug is prepared from any one of the above mRNAs and a nanocarrier for delivering the drug.

[0022] In some embodiments, the nanocarrier is a lipid nanoparticle (LNP).

[0023] In some embodiments, the lipid nanoparticles may comprise one or more of ionized lipids, PEGylated lipids, cholesterol and derivatives, and neutral auxiliary phospholipids. For example, the lipid nanoparticles may comprise any one of cationic phospholipids (ionizable lipids), neutral auxiliary phospholipids, cholesterol, and polyethylene glycol-modified phospholipids (PEGylated lipids), or a combination of any two, three, or all four.

[0024] In some embodiments, the lipid nanoparticles include SM102 or Dlin-MC3-DMA.

[0025] In some preferred embodiments, the lipid nanoparticle is SM102.

[0026] In some preferred embodiments, the material of the lipid nanoparticles is SM102:DSPC:cholesterol:DMG-PEG2000 in a mass ratio of 50±2:10±1:38.5±1:1.5±0.1.

[0027] In some embodiments, the tumor is a solid tumor.

[0028] A method for treating tumors, comprising administering to a subject an effective dose of any one of the above-mentioned interleukin-15 fusion proteins or the above-mentioned anti-tumor drug containing the mRN of the interleukin-15 fusion protein.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The present invention optimizes the protein composition of the interleukin-15 fusion protein as an IL15 superagonist, namely RLI-mono-hFc, to achieve stronger biological activity and has a significant effect of inhibiting tumor growth. The RLI-mono-hFc can be well used for treating tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1. Schematic diagram of the results comparing the biological activities of RLI-mono-hFc protein and recombinant human IL15 protein.

[0032] Figure 2. Statistical graph of IL15 superagonist biological activity detection.

[0033] Figure 3. Statistical graph of tumor volume changes in mice after drug administration.

[0034] Figure 4. Statistical graph of tumor weight in mice after drug administration.

[0035] Figure 5. Image record of mouse tumors.

[0036] Figure 6. Electrophoresis of RLI-mono-hFc IL15 superagonist protein. DETAILED DESCRIPTION

[0037] To facilitate understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the present disclosure more thorough and comprehensive.

[0038] Experimental procedures in the following examples, where specific conditions are not specified, generally followed conventional conditions, such as those in Molecular Cloning: A Laboratory Manual (4th edition, edited by Green and Sambrook, published in 2013), or according to manufacturer recommendations. All commonly used chemical reagents used in the examples were commercially available.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which this invention pertains. The terms used in this specification are for the purpose of describing specific embodiments only and are not intended to limit the invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0040] As used herein, the term "expression" or "expressing" refers to the process of transcribing a polynucleotide from a DNA template (e.g., into mRNA or other RNA transcripts) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides may be collectively referred to as "gene products" or "gene expression products." As used herein, "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of one or more nucleic acids in a cloning system or in any other context.

[0041] The terms "drug," "pharmaceutical," "therapeutic agent," or "agent useful for treatment" are used interchangeably and refer to molecules, including nucleotides or protein polypeptides, that confer a beneficial effect when administered to a subject. Beneficial effects include achieving a diagnostic determination; ameliorating a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or pathological condition; and generally combating a disease, symptom, disorder, or pathological condition.

[0042] As used herein, the term "subject" includes, but is not limited to, various animals, such as mammals, such as bovines, equines, ovines, porcines, canines, felines, lagomorphs, rodents (e.g., mice or rats), non-human primates (e.g., macaques or cynomolgus monkeys), or humans. In certain embodiments, the subject (e.g., human) suffers from a disorder (e.g., a disorder caused by a disease-associated gene defect).

[0043] The term "effective amount" or "therapeutically effective amount" refers to an amount of an agent sufficient to achieve a beneficial or desired result. A therapeutically effective amount may vary depending on one or more of the subject and disease condition being treated, the subject's weight and age, the severity of the disease condition, the mode of administration, etc., and can be readily determined by one of ordinary skill in the art.

[0044] As used herein, the term "administering or acting on or inhibiting..." to a subject can occur in vitro, ex vivo, or in vivo.

[0045] The present invention designs an IL15 superagonist and demonstrates, through comparison, that it has the strongest biological activity. This IL15 superagonist can treat tumors. Based on the characteristics of IL15, the tumor can be a solid tumor (including tumors that can be palpable as a visible mass through clinical examination, such as X-rays, CT scans, ultrasound, or palpation).

[0046] In some embodiments of the present invention, IL15, IL15Ra, Fc and linker are fused into a single protein in different forms, and the expression and biological activity of different schemes are tested.

[0047] In some embodiments of the invention, the interleukin-15 fusion protein comprises, from N-terminus to C-terminus, the CH2 and CH3 segments of the IGHE signal peptide (SP), the IL-15 receptor Rαsushi domain, the connecting peptide 1, the IL-15 functional fragment, the connecting peptide 2, and the Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N to D, one end of the IL-15 receptor αsushi domain is connected to the IL-15 functional fragment, and the other end of the IL-15 functional fragment is connected to the Fc monomer.

[0048] The present invention prepared and purified the RLI-mono-hFc protein and compared its biological activity with that of recombinant human IL-15 protein (rhIL-15). The results showed that RLI-mono-hFc could induce M07e cell proliferation at a lower concentration. The RLI-mono-hFc protein had much higher biological activity than recombinant human IL-15.

[0049] The interleukin-15 fusion protein sequence involved in the present invention has the following structure.

[0050] Table 1: Sequence Listing

[0051] The present invention is further described in detail below with reference to specific embodiments.

[0052] Example 1

[0053] 1. IL15 superagonist protein composition and experiments

[0054] 1. IL15 superagonist protein composition

[0055] This example provides the amino acid composition of IL15 superagonist (interleukin 15 fusion protein). The structures of different IL15 superagonists are shown in Table 2. For the corresponding sequences of different example groups in Table 2, please refer to the corresponding sequences in Table 1.

[0056] Table 2. Structural schemes of different IL15 superagonists used for comparison

[0057] 2 Test the effects of different linkers on the expression and biological activity of RLI-mono-hFc.

[0058] The present invention tested the effects of different linkers on the connection of various RLI-mono-hFc structures, indicating that the linkers have little effect on the biological activity of RLI-mono-hFc.

[0059] Table 3. Linkers for IL15 superagonists

[0060] 3. Testing the Ability of RLI-mono-hFc to Inhibit Tumors

[0061] The present invention tests the ability of IL15 superagonists to treat tumors. Tumor cells were injected intravenously into the right rear fat pad of mice to create a subcutaneous colon cancer tumor model. IL15 superagonist mRNA / LNPs were then injected into the mice, and the expression of the IL15 superagonist was measured, demonstrating that the IL15 superagonist mRNA can be expressed in vivo. The effects of IL15 on immune-related cells, such as T cells and NK cells, were then measured. Finally, the present invention investigated the effectiveness of IL15 superagonists in inhibiting the growth of subcutaneous colon cancer tumors in mice.

[0062] The interleukin-15 fusion protein mRNA of the present invention is prepared by in vitro transcription (IVT) method, and is used for structure and sequence screening of IL15 superagonists after capping and purification.

[0063] 3.1 Preparation of mRNA by in vitro transcription

[0064] 3.1.1 Preparation of linearized template

[0065] Plasmids for in vitro transcription were prepared by GenScript Biotech Co., Ltd. Plasmids containing candidate sequences were digested with BspQ1 enzyme. The digestion system is shown in Table 1:

[0066] Table 1 Enzyme digestion system

[0067] Incubate at 50°C for 2-3 hours.

[0068] 3.1.2 Linearized template purification

[0069] (1) Add 200 μl of DNA purification magnetic beads, mix well, and incubate at room temperature for 10 minutes.

[0070] (2) Place the sample on a magnetic rack for 5 minutes and discard the supernatant.

[0071] (3) Add 200 μl of 80% ethanol and incubate at room temperature for 30 seconds.

[0072] (4) Incubate on the magnetic stand for 5 minutes, discard the supernatant, and repeat twice.

[0073] (5) Aspirate the ethanol and let it air dry at room temperature for 10 minutes. Add 100 μl of Nuclease-free water, vortex to mix the beads, incubate at room temperature for 5 minutes, and place on a magnetic stand for 5 minutes.

[0074] (6) Aspirate the supernatant and retain it to measure the concentration.

[0075] 3.1.3 In vitro transcription

[0076] (1) Vortex and mix all components except T7 RNA Polymerase Mix, centrifuge briefly to collect the contents at the bottom of the tube, and store on ice until ready to use. Prepare the system according to Table 2 below.

[0077] Table 2 In vitro transcription reaction system

[0078] Add 1 μl RNase inhibitor to 20 μl system.

[0079] (2) Gently mix the components with a pipette, collect them by brief centrifugation, and incubate at 37°C for 2 h.

[0080] (3) Add 1 μl of DNase I to the reaction system and incubate at 37°C for 15 min to digest the transcribed DNA template.

[0081] (4) Purification: Follow the conventional linearized template purification and use VAHTS RNA Clean Beads for purification.

[0082] 3.1.4 RNA capping and purification

[0083] (1) Take 50 μg RNA into a 1.5 ml centrifuge tube and dilute it to 65% using RNase-Free ddH20.

[0084] μl, heated at 65°C for 5 min.

[0085] (2) Place the heated centrifuge tube on ice for 5 minutes.

[0086] (3) Add the components as shown in Table 3:

[0087] Table 3 RNA capping and purification reaction system

[0088] Add 1 μl RNase inhibitor to 20 μl system and incubate at 37°C for 1 hour.

[0089] (4) Conventional purification method requires purification using VAHTS RNA Clean Beads.

[0090] 3.2 Preparation of mRNA / LNP

[0091] 3.2.1 Dissolve the prepared mRNA on ice and dilute to 100 ng / μl with 50 mM sodium citrate buffer to form the aqueous phase. Prepare the ethanol phase using anhydrous ethanol as the solvent, using a ratio of SM102 (or Dlin-MC3-DMA): DSPC: cholesterol: DMG-PEG2000 of 50:10:38.5:1.5, resulting in an SM102 concentration of 5.62 mg / ml and a total liposome concentration of 10.28 mg / ml.

[0092] 3.2.2 The aqueous and ethanol phases were coated using a nanomedicine preparation system (INano L, Maiana (Shanghai) Instrument Technology Co., Ltd.) at a flow rate ratio of 3:1 for the aqueous phase:ethanol phase, with a total flow rate of 12 mL / min. The LNPs were collected and diluted three-fold with RNase-free water and placed in a 100 kD dialysis bag. The dialysis bag was then dialyzed against 200 volumes of LNP-containing 1X PBS with a magnetic stirrer at 300 rpm for 18 h at room temperature. The collected LNPs in the dialysis bag were sterile-filtered using a 0.22 μm filter membrane. The filtered LNPs were then centrifuged through a 100 kD ultrafiltration tube at 3000 rpm at 4°C for 90 min. The LNPs in the ultrafiltration tube were collected and rinsed with 1X PBS to remove any residual LNPs. The mRNA / LNPs were then mixed with the previously prepared LNPs and stored in the dark at 2-8°C.

[0093] 2. The test also includes the following experiments:

[0094] 1. Electrophoresis

[0095] 1. Run the gel: Remove the seal from the 4-12% Bis-Tris gel and place it in the electrophoresis tank. Add sufficient 1x SDS Running Buffer and rinse the wells three times with Running Buffer. After rinsing, load the samples in the following order, loading 20 μl of each sample. Connect the electrodes to the electrophoresis instrument, adjust the constant voltage to 200 V, and run for approximately 40 minutes.

[0096] 2. Transfer: ① Cut the PVDF membrane to the size of the gel and create a notch in the upper right corner as a guide. Soak the membrane in methanol for 30 minutes to activate. ② Transfer: After electrophoresis, remove the gel from the gel sheet and soak it in transfer buffer. Assemble the transfer splint in the order of sponge, two layers of filter paper, gel, PVDF membrane, two layers of filter paper, and sponge. Place the transfer splint in the electrophoresis tank filled with transfer buffer. Connect the electrophoresis instrument and run at a constant voltage of 90V for 80 minutes.

[0097] 3. Blocking: Take out the membrane and place it in an incubation box containing 10 ml of 5% skim milk powder, place it on a shaker at 80 rpm, and incubate at room temperature for 1 hour.

[0098] 4. Membrane Washing: Recover the milk and store at 4°C. Wash the membrane three times with 1x TBST, shaking on a 130 rpm platform for 10 min each time.

[0099] 6. Incubation with primary antibody: Prepare IL-15 antibody according to the recommended dilution (20ul antibody + 10ml TBST), place the membrane in the incubation box containing the antibody, shake on 80rpm, incubate at room temperature for 1h, incubate at 4℃ overnight.

[0100] 7. Wash the membrane: Recover the primary antibody used in the previous incubation and store at -20°C. Wash the membrane three times with TBST, shaking on a 130 rpm platform for 10 minutes each time.

[0101] 2. Incubate with secondary antibody: Prepare 2 μl of goat anti-rabbit IgG / horseradish peroxidase conjugate in 10 ml of 0.5% skim milk powder. Pour off the TBST and add 10 ml of secondary antibody solution. Incubate on a shaker at 80 rpm for 1 hour at room temperature.

[0102] 3. Wash the membrane: Recover the secondary antibody and store at -20°C. Wash the membrane three times with TBST at 130 rpm for 10 min each time.

[0103] 4. Development (avoid light): Use ECL luminescent liquid to expose the effect of the film.

[0104] 2. IL15 superagonist biological activity detection

[0105] 1. Cell Starvation: Take M07e cells in the logarithmic growth phase, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and wash twice with PBS. Resuspend in 1640 cytokine-free medium containing 20% ​​serum (add 40 ml of 1640 basal medium to 10 ml of serum). Take 20 μl of the cell suspension and add 20 μl of AOPI staining solution. Mix thoroughly, place in a cell counting plate, and count on a cell counter. Record the viable cell density and cell viability. Take an excess of the cell suspension based on the viable cell concentration and starve incubate in a CO2 incubator for 4 hours.

[0106] 2. Prepare mRNA suitable for transfection, transfect 1 μg per well (n=3), and set up a culture medium control without cytokines.

[0107] 3. Cell plating: After starvation treatment, centrifuge the cells at 1000 rpm for 5 minutes, discard the supernatant, and resuspend them in Opti-MEM medium. Take 20ul of cell suspension and add 20ul of AOPI dye solution, mix well, add the cell counting plate and insert the cell counter to count: record the viable cell density and cell viability. Take the corresponding volume of cell suspension according to the viable cell density, add appropriate amount of Opti-MEM medium to make 4ml3x10 5 Cells / ml cell suspension. Because proliferation assays require luminescence measurements, and adjacent wells of transparent culture plates can interfere with signal signal, cells were plated on separate wells of the transparent plate. 50 μl of cell suspension (i.e., 1.5 x 104 cells / well) or Opti-MEM medium (negative control) was added to each well. Except for the negative control wells, 1 μg of mRNA was transfected into each well (n=3). Due to marginal evaporation from culture plates, 100 μl of PBS was added to the outermost wells. The plated cells were placed in a CO2 incubator and cultured for 24 / 48 hours.

[0108] 4. Cell viability detection: Take out the cell culture plate and equilibrate it at room temperature for 10 minutes (usually not more than 30 minutes), add 100ul CellTiter-Lumi TM Add the Plus Luminescence Detection Reagent and shake at room temperature for 2 minutes to promote cell lysis. Then, incubate for 10 minutes to allow the luminescence signal to stabilize. Perform chemiluminescence detection using a multi-function microplate reader.

[0109] 3. Subcutaneous colon cancer (CT26) tumor model

[0110] The tumor cells were washed twice with PBS and the cell concentration was adjusted to 5 × 10 6 / mL, subcutaneously injected into the right rear fat pad of mice, 100 μL / mouse, i.e. 5×10 5 / mice.

[0111] The specific steps include: inoculating CT26 cells into the right posterior fat pad of 50 female BALB / c mice, and waiting for the tumor to grow to 20-40 mm. 3 At 4 hr, mice were divided into groups and dosed according to tumor volume. The day of dosing was designated Day 0. The control group received PBS, while the remaining two groups received 5 μg or 10 μg of RLI-mono-hFc-expressing mRNA / LNP. Each group consisted of 8 mice. During the experiment, mouse body weight and tumor volume were recorded. At the end of the experiment, tumor-bearing mice were euthanized, and their tumors were weighed and photographed.

[0112] 3. Experimental Results

[0113] 1. Characteristics of the RLI-mono-hFc IL15 superagonist protein

[0114] As shown in Figure 6 , the RLI-mono-hFc IL15 superagonist is a protein with a molecular weight of approximately 70 kd. mRNA of SEQ ID NO. 9 was transfected into A375 cells. After 24 hours, the supernatant was collected and assayed for secreted RLI-mono-hFc IL15 superagonist. The transfection and electrophoresis methods are described above under "IL15 superagonist biological activity assay" and "electrophoresis."

[0115] Protein structure will affect its expression and work. The present invention will compare the designed IL15 superagonist structure (RLI-mono-hFc) with IL15 superagonist candidates of other structures to prove that it has advantages in terms of expression and biological activity (Table 1). M07e is a cell line of megakaryocytes that responds to IL15 stimulation and proliferates. The ability of IL15 superagonists to stimulate M07e proliferation is an indicator reflecting the function of IL15 superagonists. The IL15 superagonist of the present invention is currently much higher than wild-type IL15 in biological activity (Figure 1). Different amounts of RLI-mono-hFc and recombinant human IL15 (rhIL15) purchased from commercial channels were added to the M07e culture medium, and cell viability (i.e., the number of living cells) was detected after 48 hours to achieve the effect of comparing the biological activity of RLI-mono-hFc IL15 superagonist and wild-type human IL15. Results showed that the EC50 of RLI-mono-hFc was significantly lower than that of wild-type human IL-15 (0.48 vs. 3.37), demonstrating a significant improvement in biological activity. IL-15 is recognized for its ability to promote the proliferation of T cells and NK cells, both of which are immune cells directly involved in killing tumor cells. IL-15 plays a crucial role in tumor suppression, and the IL-15 superagonist RLI-mono-hFc, with biological activity far exceeding that of wild-type IL-15, has potent anti-tumor potential.

[0116] 2. IL15 superagonist biological activity detection

[0117] By fusing IL15, IL15Ra, Fc and linker in different forms into one protein, their biological activities were compared and the effects of different linkers on the biological activity of RLI-mono-hFc were tested.

[0118] mRNA suitable for transfection was prepared by in vitro transcription (IVT) and incubated with Mo7e cells for 24 hours. Cell viability (i.e., number of viable cells) was then measured for biological activity comparison. As shown in Figure 2, RLI-mono-hFc exhibited the highest cell viability, demonstrating that the RLI-mono-hFc of the present invention exhibits superior biological activity compared to other IL15 superagonists composed of other sequences. As shown in Figure 2, RLI-mono-hFc exhibited greater biological activity than ILR-mono-hFc, suggesting that placing the IL-15 receptor Rα sushi domain in front of the functional IL15 fragment is more beneficial for IL15 superagonist function. RLI-mono-hFc also exhibited greater biological activity than mono-hFc-RLI and mono-hFc-ILR, suggesting that placing the hFc in front does not improve IL15 function. The two tested linkers, linker2 and linker3, also had good biological activity of IL15 fusion protein after being used as components of the fusion protein (other components were the same as RLI-mono-hFc), but not as good as linker1, suggesting that linker1 was the most beneficial to the fusion protein.

[0119] 3. Observation of the tumor inhibition effect of RLI-mono-hFc

[0120] By constructing a mouse subcutaneous colon cancer (CT26) tumor model, the tumor inhibition effect of different doses of RLI-mono-hFc in the BALB / c mouse CT26 subcutaneous tumor model was observed. From the tumor inhibition results (Figure 3), compared with the PBS control group, RLI-mono-hFc (5ug) and RLI-mono-hFc (10ug) inhibited the growth of mouse colon cancer (CT26) tumors. Compared with the control group, the tumor growth inhibition rate (TGI) of RLI-mono-hFc (5ug) was 10.37%. TV ) was 55.23%, and the tumor growth inhibition rate (TGI TV Compared with the control group, RLI-mono-hFc (10 μg) had a significant effect in inhibiting tumor growth.

[0121] From the statistical results of tumor weight (Figure 4), compared with the control group, the tumor growth inhibition rate (TGI Tw ) was 47.51%, and the tumor growth inhibition rate (TGI Tw) was 86.48%. Tumor records (Figure 5) show that two mice (1 / 4) in the RLI-mono-hFc (5 μg) group experienced tumor regression, while five mice (5 / 8) in the RLI-mono-hFc (10 μg) group experienced tumor regression. These experimental results demonstrate that the IL15 superagonist RLI-mono-hFc of the present invention effectively inhibits the growth of mouse colon cancer (CT26). The IL15 superagonist RLI-mono-hFc can be used for tumor treatment.

[0122] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the patent for this invention shall be determined by the appended claims.

Claims

1. An interleukin-15 fusion protein, characterized in that: From the N-terminus to the C-terminus, it includes, in sequence, the CH2 and CH3 segments of the IGHE signal peptide, the IL-15 receptor Rαsushi domain, the connecting peptide 1, the IL-15 functional fragment, the connecting peptide 2 and the Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N to D.

2. The interleukin-15 fusion protein according to claim 1, characterized in that: The sequence of the IGHE signal peptide is shown in SEQ ID NO:

11.

3. The interleukin-15 fusion protein according to claim 1, characterized in that: The IL-15 receptor Rαsushi domain is shown in SEQ ID NO:

12.

4. The interleukin-15 fusion protein according to claim 1, characterized in that: The CH2 and CH3 segments of the Fc monomer are shown in SEQ ID NO:

13.

5. The interleukin-15 fusion protein according to any one of claims 1 to 4, characterized in that: The connecting peptide 1 and the connecting peptide 2 are shown in SEQ ID NO:

14.

6. The interleukin-15 fusion protein according to any one of claims 1 to 4, characterized in that: The amino acid sequence of the interleukin-15 fusion protein is shown in SEQ ID NO.

1.

7. The mRNA of the interleukin-15 fusion protein according to any one of claims 1 to 6.

8. The mRNA according to claim 7, which is shown in SEQ ID NO.

9.

9. Use of the interleukin-15 fusion protein according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.

10. Use of the interleukin-15 fusion protein mRNA according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.

11. An anti-tumor drug, wherein: The anti-tumor drug is prepared from the mRNA according to claim 7 or 8 and a nanocarrier for delivering the drug.

12. The anti-tumor drug according to claim 11, wherein The nanocarrier is a lipid nanoparticle.

13. A method for treating a tumor, wherein: An effective dose of the interleukin-15 fusion protein according to any one of claims 1 to 6, the mRNA according to claim 7, or the anti-tumor drug according to any one of claims 11 to 12 is administered to a subject.

Citation Information

Patent Citations

  • Methods for identification of sites for IGG conjugation

    CN106117348A

  • Therapeutic compounds and methods

    CN108697736A

  • Fusion protein prodrug taking interleukin 15 as active ingredient

    CN110437339A

  • Tethered interleukin-15 and interleukin-21

    CN111868246A

  • Il-15 / il-15ra heterodimeric fc fusion proteins and uses thereof

    CN112105645A